Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Dendritic-Cell Immunotherapy Plus Temozolomide Following Surgery and Chemoradiation in Patients With Newly Diagnosed Glioblastoma

NCT02649582 is registered in ClinicalTrials.gov with University Hospital, Antwerp as lead sponsor.

NCT NCT02649582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02649582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Dendritic-Cell Immunotherapy Plus Temozolomide Following Surgery and Chemoradiation in Patients With Newly Diagnosed Glioblastoma
Lead sponsor
University Hospital, Antwerp
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 31, 2015
Completion date
July 31, 2027
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme of brain